TLP Group’s Acadia Pharmaceuticals ACAD Stock Holding History

TLP Group’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-180	Closed	-$5K	–	372
2017 Q4	$5K	Buy	+180	New	+$5.76K	﹤0.01%	441

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

TLP Group's ACAD Position: Q1 2018 in Review

TLP Group sold out of Acadia Pharmaceuticals (ACAD) in Q1 2018, closing a stake of 180 shares — an estimated $5K sold.

TLP Group first reported a position in ACAD in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 196 funds tracked by Wall St. Rank hold ACAD as of Q1 2018.

TLP Group reported no remaining Acadia Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
TLP Group sold 180 Acadia Pharmaceuticals shares in Q1 2018, an estimated $5K.
TLP Group first reported a position in Acadia Pharmaceuticals in Q4 2017 and held it in 1 quarter.
TLP Group's Acadia Pharmaceuticals position peaked at $5K in Q4 2017.
196 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2018.

Based on TLP Group's 13F filing for Q1 2018, filed 16 May 2018.